AletheiaHQ
Sign In
DIR-E8-Q2S-7CYK/LVL 5·Leveraged OperationsHigh-leverage, capital-intensive cell operations. Requires fronted capital or established legal infrastructure. Examples: fronting $10k to lease warehouse space ahead of a known logistics fracture; forming a joint entity to secure and sub-license a dormant government patent for recurring royalties./80% confidence
Return to Directory

Arbitrage SBIR Vendor Selection via FOIA-Powered CRO Matchmaking Platform

Organization
NSF SBIR program's structural gap between funding allocation and vendor intelligence provision
Sector
Specialized Contract Research Organizations seeking qualified SBIR-funded clients with guaranteed budgets
Location
National (US-focused)

Source Reference

https://www.nsf.gov/awardsearch/showAward?AWD_ID=2538091

// Venture Capital// Backend// Biotech// Data Scraping// Open-Source Intelligence// Digital Commodities// Health Policy & Regulation// Data Engineering & Pipelines

Executive Context

NSF awarded $305,000 SBIR Phase I funding to ENDURE BIOTHERAPEUTICS for a PKU microbiome therapeutic platform, creating a 6-month window where the company must prove technical feasibility but lacks strategic guidance, vendor intelligence, and IP protection for the critical Phase II transition required for survival.

Catalyst / Timing

The arbitrage between ENDURE's immediate $305k cash (with 6-month expiration) and their complete lack of time/connections to identify and vet CROs with proven SBIR Phase II success rates. The SBIR system gives money but no vendor intelligence, creating a 15-25% margin opportunity for curated access.

Projected Yield

15% fee on $200k average CRO contract × 50 SBIR Phase I companies/year = $1.5M annual revenue

Structural Friction

• Vulnerability: The arbitrage between ENDURE's immediate $305k cash (with 6-month expiration) and their complete lack of time/connections to identify and vet CROs with proven SBIR Phase II success rates. The SBIR system gives money but no vendor intelligence, creating a 15-25% margin opportunity for curated access. • Capital yield: 15% fee on $200k average CRO contract × 50 SBIR Phase I companies/year = $1.5M annual revenue • Resource capture: Exclusive FOIA-derived dataset of what CRO characteristics actually drive Phase II success • Influence capture: Gatekeeper position between desperate SBIR companies and specialized CROs • Sovereignty yield: Platform lock-in through vendor exclusivity agreements and proprietary success correlation data • Required vectors: Vector: FOIA & Government Data Acquisition, Vector: Platform Development & Tech, Vector: Biotech CRO Industry Knowledge, Vector: Business Development & Commission Sales

Required Capabilities

  • Vector: FOIA & Government Data Acquisition

    Primary executor: Phase 1: FOIA Data Acquisition: File Freedom of Information Act (FOIA) request with NSF for all SBIR Phase I award data

  • Vector: Platform Development & Tech

    Supporting vector for: Arbitrage SBIR Vendor Selection via FOIA-Powered CRO Matchmaking Platform

  • Vector: Biotech CRO Industry Knowledge

    Supporting vector for: Arbitrage SBIR Vendor Selection via FOIA-Powered CRO Matchmaking Platform

  • Vector: Business Development & Commission Sales

    Supporting vector for: Arbitrage SBIR Vendor Selection via FOIA-Powered CRO Matchmaking Platform

Execution Protocol

Execution Protocol Locked

A one-time payment of $1799 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.

This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.